BioSpace News Archive

Biotage’s 2020 Annual Report, Corporate Governance Report and Remuneration Report are as of today available at: www.biotage.com This is information that Biotage AB (publ) is obliged to make public pursuant to the Securities Markets Act.

Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS).

Harmony™ Transcatheter Pulmonary Valve is First Minimally Invasive Alternative for Patients with Severe Pulmonary Regurgitation Who Have a Native or Surgically-Repaired Right Ventricular Outflow Tract

Avea Solutions, a leading provider of behavioral health software solutions, has raised a new round of funding to enable its next phase of rapid growth.

CEO Amir Jafri will demonstrate how his FDA Breakthrough Device’s platform-based, subtractive therapy business model optimizes standard of care and shareholder value.

NEOGEN Corporation (NASDAQ: NEOG) announced that, at the conclusion of its sponsorship agreement with the National FFA Organization, the company made a $25,000 donation aimed at supporting agricultural education and fighting the spread of COVID-19.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has closed its previously announced private placement, which resulted in gross proceeds to Second Sight of $27.9 million, before deducting offering expenses.

The management of Seneca Biopharma, Inc. and Leading BioSciences, Inc. have each received inquiries regarding Seneca’s special meeting of stockholders that was convened on March 24, 2021 and adjourned to April 9, 2021.

Kiromic BioPharma, Inc. (Nasdaq: KRBP ) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics. Today, the Company announced an interview with the CEO, Dr. Maurizio Chiriva-Internati, which will air on The RedChip Money Report on the Bloomberg Network.

Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type ( BRCA -wt) profile and homologous recombination proficiency (HRP) have been published in Gynecologic Oncology. Patients treated with Vigil experienced improved overall survival (OS) and recurrence free survival (RFS) compared to placebo. No Grade 3 or 4 toxicities were observed in the Vigil-treated group.